IMPORTANT NOTE: This paper was officially RETRACTED on July 31, 2025. The following summary describes the study’s claims and methodology as published in 2017, but these findings should no longer be considered part of the reliable scientific record.
Abstract
There is increasing interest in the association between depression and the development of metabolic diseases. Rosiglitazone, a therapeutic drug used to treat type 2 diabetes mellitus, has shown neuroprotective effects in patients with stroke and Alzheimer's disease. The present study was performed to evaluate the possible roles of rosiglitazone in in vivo (unpredictable chronic mild stress-induced depressive mouse model) and in vitro (corticosterone-induced cellular model) depressive models. The results showed that rosiglitazone reversed depressive behaviors in mice, as indicated by the forced swimming test and open field test. Rosiglitazone was also found to inhibit the inflammatory response, decrease corticosterone levels, and promote astrocyte proliferation and neuronal axon plasticity in the prefrontal cortex of mice. This series of in vivo and in vitro experiments showed that autophagy among neurons was inhibited in depressive models and that rosiglitazone promoted autophagy by upregulating LKB1, which exerted neuroprotective effects. Rosiglitazone was also found to activate the Akt/CREB pathway by increasing IGF-1R expression and IGF-1 protein levels, thereby playing an anti-apoptotic role in astrocytes. Rosiglitazone's autophagy promotion and neuroprotective effects were found to be reversed by the PPARγ antagonist T0070907 in primary neurons and by PPARγ knockdown in an N2a cell line. In conclusion, we found that rosiglitazone protects both neurons and astrocytes in in vivo and in vitro depressive models, thereby playing an anti-depressive role. These findings suggest that PPARγ could be a new target in the development of anti-depressive drugs.
Introduction: Metabolic Links to Mood Regulation
Major Depressive Disorder (MDD) is increasingly recognized as having a significant metabolic component. However, the precise cellular mechanisms linking metabolic pathways to mood regulation remain poorly understood. This study focuses on the prefrontal cortex (PFC), a critical brain region for emotional regulation that often exhibits inflammation and cellular degradation in depressive states.
The researchers investigated two specific cellular failures associated with depression: the deficiency of neuronal autophagy (the process by which cells clear damaged components) and astrocytic apoptosis (programmed death of support cells). They hypothesized that Rosiglitazone, a PPARγ agonist typically used for insulin sensitization in type 2 diabetes, could cross the blood-brain barrier to address these cellular deficits.
Experimental Methodology
The study employed a multi-level approach to test the efficacy of Rosiglitazone:
- In Vivo Models: C57BL/6 mice were subjected to an Unpredictable Chronic Mild Stress (UCMS) protocol for six weeks to induce depressive-like behaviors. Treatment groups received either Rosiglitazone or Fluoxetine (a standard antidepressant) for the final six weeks of the stress period.
- In Vitro Models: Primary cortical neurons, astrocytes, and N2a cells were treated with high doses of corticosterone (CORT) to simulate stress-induced hormonal environments.
- Behavioral and Molecular Assays: Behavioral recovery was assessed via the Sucrose Preference Test, Forced Swimming Test (FST), and Open Field Test (OFT). Molecular changes were tracked using Western Blotting, qRT-PCR, and Transmission Electron Microscopy (TEM) to count autophagosomes.
Key Results and Behavioral Recovery
The study reported that Rosiglitazone treatment significantly mitigated the behavioral deficits induced by UCMS. As shown in Figure 1, treated mice exhibited a restoration of body weight and a significant increase in sucrose preference compared to the UCMS-only group. Furthermore, Rosiglitazone reduced immobility in the Forced Swimming Test and increased exploration in the Open Field Test, indicating a reduction in behavioral despair and anxiety-like symptoms.
At the cellular level, the authors claimed a dual-protection mechanism:
- Neuronal Autophagy: Rosiglitazone activated the LKB1/AMPK pathway, increasing markers of autophagy (such as the LC3II/I ratio) and the physical presence of autophagosomes in neurons.
- Astrocyte Survival: The drug activated the IGF-1R/Akt/CREB pathway, which shifted the balance of apoptotic proteins (lowering BAX and raising Bcl2), thereby preventing astrocyte death.
Discussion and Limitations
While the study suggests that PPARγ is a critical "master switch" for neuroprotection in the PFC, several significant caveats remain. Most importantly, the paper's retraction in 2025 raises fundamental concerns regarding the integrity and reproducibility of the data presented.
Additionally, Rosiglitazone has a complex clinical history due to cardiovascular risks, which complicates its potential transition to a psychiatric treatment. While the mapping of the LKB1 and Akt/CREB pathways provides a theoretical framework for how metabolic drugs might influence brain health, the translation of these mouse-model findings to human clinical depression remains speculative, especially given the retraction status of the original work.
Summary updated